Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Emily N. Neubert"'
Autor:
Emily N. Neubert, Julia M. DeRogatis, Sloan A. Lewis, Karla M. Viramontes, Pedro Ortega, Monique L. Henriquez, Rémi Buisson, Ilhem Messaoudi, Roberto Tinoco
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Chronic infections and cancers evade the host immune system through mechanisms that induce T cell exhaustion. The heterogeneity within the exhausted CD8+ T cell pool has revealed the importance of stem-like progenitor (Tpex) and terminal (Te
Externí odkaz:
https://doaj.org/article/b44f60fe707f457086ec7ed34eebb20f
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Chronic viral infections where the antigen persists long-term, induces an exhaustion phenotype in responding T cells. It is now evident that immune checkpoints on T cells including PD-1, CTLA-4, and PSGL-1 (Selplg) are linked with the differentiation
Externí odkaz:
https://doaj.org/article/c91548b5f252491c881c17c8abe287b1
Autor:
Roberto Tinoco, Emily N. Neubert, Christopher J. Stairiker, Monique L. Henriquez, Linda M. Bradley
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Effective T cell differentiation during acute virus infections leads to the generation of effector T cells that mediate viral clearance, as well as memory T cells that confer protection against subsequent reinfection. While inhibitory immune checkpoi
Externí odkaz:
https://doaj.org/article/b9bcee28e3d24f1e9ef09d6a55c91578
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkp
Externí odkaz:
https://doaj.org/article/c5de6ef2272846188c21fadd269bf0ed
Autor:
Julia M. DeRogatis, Emily N. Neubert, Karla M. Viramontes, Monique L. Henriquez, Dequina A. Nicholas, Roberto Tinoco
Publikováno v:
Journal of Virology. 97
Our study shows how CD38 expression is regulated on CD8 + T cells responding during acute and chronic viral infection. We observed higher CD38 levels on CD8 + T cells during chronic viral infection compared to levels during acute viral infection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1e17d9727548a40a6b554ede9f5b37b
https://doi.org/10.1128/jvi.00225-23
https://doi.org/10.1128/jvi.00225-23
Autor:
Roberto Tinoco, Christian F. Guerrero-Juarez, Monique L. Henriquez, Emily N. Neubert, Karla M. Viramontes, Julia M. DeRogatis
Immune-checkpoint inhibitors have had impressive efficacy in some patients with cancer, reinvigorating long-term durable immune responses against tumors. Despite the clinical success of these therapies, most patients with cancer continue to be unresp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66585dd96b7b2c39036ab95aa9a89e1a
https://doi.org/10.1158/2326-6066.c.6550661
https://doi.org/10.1158/2326-6066.c.6550661
Autor:
Roberto Tinoco, Christian F. Guerrero-Juarez, Monique L. Henriquez, Emily N. Neubert, Karla M. Viramontes, Julia M. DeRogatis
Supplementary Table from Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1–Resistant Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6259469b69f80f1d0751100c893ebf0e
https://doi.org/10.1158/2326-6066.22544492.v1
https://doi.org/10.1158/2326-6066.22544492.v1
Autor:
Roberto Tinoco, Christian F. Guerrero-Juarez, Monique L. Henriquez, Emily N. Neubert, Karla M. Viramontes, Julia M. DeRogatis
Supplementary Figure from Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1–Resistant Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3581e71cfae526664c6540bf0559d9da
https://doi.org/10.1158/2326-6066.22544495.v1
https://doi.org/10.1158/2326-6066.22544495.v1
Autor:
Julia M. DeRogatis, Karla M. Viramontes, Emily N. Neubert, Monique L. Henriquez, Christian F. Guerrero-Juarez, Roberto Tinoco
Publikováno v:
Cancer immunology research, vol 10, iss 5
Cancer Immunol Res
Cancer Immunol Res
Immune-checkpoint inhibitors have had impressive efficacy in some patients with cancer, reinvigorating long-term durable immune responses against tumors. Despite the clinical success of these therapies, most patients with cancer continue to be unresp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6ec51cafbf7dde771abbd17b0269876
https://escholarship.org/uc/item/4gj6s3nq
https://escholarship.org/uc/item/4gj6s3nq
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77ecd60f902f47507068665cfb4a4e9
https://doi.org/10.3389/fimmu.2021.636238
https://doi.org/10.3389/fimmu.2021.636238